2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-W419570
    (Rac)-BX 048 478005-11-7 98%
    (Rac)-BX 048 is a BX 048 racemate. BX 048 is a P2Y12 receptor antagonist. BX 048 inhibits ADP-induced platelet aggregation in human, dog and rat whole blood. BX 048 also inhibits Arachidonic acid (HY-109590) induced platelet aggregation (IC50 of 15 μM).
    (Rac)-BX 048
  • HY-W472509
    11-HETE 73804-65-6 98%
    11-HETE (11-Hydroxy-5,8,12,14-eicosatetraenoic acid) is the activator for cytochrome P450. 11-HETE upregulates the mRNA expressions of CYP1B1, CYP1A1, CYP4A11, CYP4F11, and CYP4F2, induces cell hypertrophy in RL-14 cell, and exhibits potential to be used in cardiovascular diseases.
    11-HETE
  • HY-W581820
    Iron(II) succinate 10030-90-7 98%
    Iron(II) succinate (Ferrous succinate) is an orally active and organic acid iron supplement (ferrous salt). Iron(II) succinate improves hematological parameters in iron-deficiency anemia rats, including hemoglobin, red blood cells, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration. Iron(II) succinate increases serum ferritin, serum iron levels, and transferrin saturation, while decreasing total iron-binding capacity in iron-deficiency anemia rats. Iron(II) succinate reduces the elevated heart, spleen, and kidney coefficients, and increases the decreased liver coefficient in iron-deficiency anemia rats. Iron(II) succinate replenishes the depleted iron content in the liver and spleen of iron-deficiency anemia rats. Iron(II) succinate can be used for the research of iron-deficiency anemia.
    Iron(II) succinate
  • HY-W585934
    Fructose-phenylalanine 31105-03-0 98%
    Fructose-phenylalanine (Fru-Phe) is a non-competitive angiotensin-converting enzyme (ACE) inhibitor (IC50 =0.19 mM) with antioxidant activities. Fructose-phenylalanine forms a stable complex with Zn2+ ions at the ACE active site, blocking the conversion of angiotensin I to II and thereby lowering blood pressure. Fructose-phenylalanine is promising for research of cardiovascular diseases.
    Fructose-phenylalanine
  • HY-W587489
    RL-603 444904-63-6 98%
    RL-603 is the metabolite of Anagrelide (HY-B0523). RL-603 exhibits platelet-lowering activity in mouse model.
    RL-603
  • HY-W587516
    Bisphenol A bissulfate disodium 10040-44-5 98%
    Bisphenol A bissulfate disodium is a metabolite of Bisphenol A (HY-18260). Bisphenol A bissulfate disodium (compound 7) show complement-inhibiting activity with an IC50 of 247 μM.
    Bisphenol A bissulfate disodium
  • HY-W588266
    Isopropyl 5-(diphenylphosphoryl)pentanoate 2088449-88-9 98%
    Isopropyl 5-(diphenylphosphoryl)pentanoate is the impurity of Latanoprost (HY-B0577).
    Isopropyl 5-(diphenylphosphoryl)pentanoate
  • HY-W650803
    Nemazoline 130759-56-7 98%
    Nemazoline (A-57219) is selective α-adrenergic agent with α1-agonist/α2-antagonist activity, which is used as a nasal decongestant. Nemazoline produces decongestion by α1-mediated contraction of capacitance vessels, but not compromises blood flow by virtue of α2-antagonism. Nemazoline also blocks endogenous noradrenaline-mediated α 2-constriction of the resistance vessels.
    Nemazoline
  • HY-W653978
    Cinacalcet-d4 hydrochloride 2514927-75-2 98%
    Cinacalcet-d4 (AMG-073-d4) hydrochlorideis deuterium labeled Cinacalcet (hydrochloride). Cinacalcet hydrochloride (AMG-073 hydrochloride) is an orally active, allosteric agonist of Ca receptor (CaR), used for cardiovascular disease treatment.
    Cinacalcet-d4 hydrochloride
  • HY-W699430
    Norverapamil-d6 hydrochloride 1329651-21-9 98%
    Norverapamil-d6 ((±)-Norverapamil-d6) hydrochloride is deuterium labeled Norverapamil (hydrochloride). Norverapamil hydrochloride ((±)-Norverapamil hydrochloride), an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor.
    Norverapamil-d6 hydrochloride
  • HY-W700344
    o-Desmethyl ranolazine 172430-45-4 98%
    o-Desmethyl ranolazine (CVT-2514; RS-88390) is a metabolite of Ranolazine (HY-B0280), formed through metabolism of Ranolazine by enzymes of the cytochrome P450 (CYP) 3A family.
    o-Desmethyl ranolazine
  • HY-W701877
    Latanoprost tris(triethylsilyl) ether 477884-78-9 98%
    Latanoprost tris(triethylsilyl) ether is a precursor in the synthesis of the prostaglandin F2α (PGF2α) receptor (FP receptor) agonist Latanoprost (HY-B0577).
    Latanoprost tris(triethylsilyl) ether
  • HY-W704938
    Amlodipine metabolite 113994-45-9 98%
    Amlodipine metabolite is a major metabolite of the calcium channel inhibitor Amlodipine (HY-B0317).
    Amlodipine metabolite
  • HY-W704968
    2-Oxo-zoniporide hydrochloride 372078-42-7 98%
    2-Oxo-zoniporide hydrochloride is an oral active sodium-hydrogen exchanger type 1 (NHE-1) inhibitor and can be used for study of myocardial ischemic injury.
    2-Oxo-zoniporide hydrochloride
  • HY-W706573
    (S)-(-)-Nitrendipine 80873-62-7 98%
    (S)-(-)-Nitrendipine ((S)-(-)-BAY-E-5009) is an isomer of Nitrendipine (HY-B0424). Nitrendipine acts as a calcium channel blocker. (S)-(-)-Nitrendipine can be used for research on hypertension.
    (S)-(-)-Nitrendipine
  • HY-W707384
    Candesartan Cilexetil-d11 1261393-19-4 98%
    Candesartan Cilexetil-d11 (TCV-116-d11) is deuterium labeled Candesartan Cilexetil. Candesartan Cilexetil (TCV-116) is an angiotensin II receptor inhibitor. Candesartan Cilexetil ameliorates the pulmonary fibrosis and has antiviral and skin wound healing effect. Candesartan Cilexetil can be used for the research of high blood pressure.
    Candesartan Cilexetil-d11
  • HY-W707517
    Famotidine-d4 2707433-64-3 98%
    Famotidine-d4 (MK-208-d4) is deuterium labeled Famotidine. Famotidine (MK-208) is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
    Famotidine-d4
  • HY-W713365
    Eltrombopag-d3 1133710-20-9 98%
    Eltrombopag-d3 (SB-497115-d3) is deuterium labeled Eltrombopag. Eltrombopag (SB-497115) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well.
    Eltrombopag-d3
  • HY-W714833
    2-(2-Hydroxypropionylamino)-benzamide 18326-27-7 98%
    2-(2-Hydroxypropionylamino)-benzamide is a fungal metabolite with proangiogenic activities.
    2-(2-Hydroxypropionylamino)-benzamide
  • HY-W715812
    Bromuconazole 116255-48-2 98%
    Bromuconazole is a triazole fungicide with oral efficacy and blood-brain barrier permeability. Bromuconazole protects crops from various fungal contaminations. Bromuconazole exhibits cytotoxicity against a variety of cancer cells, induces G0/G1 cell cycle arrest and inhibits DNA synthesis in cancer cells, and triggers cytoskeletal structural disorder, genotoxic damage, apoptotic (apoptosis) cell death, and mitochondrial membrane depolarization. Bromuconazole activates caspase-3, induces excessive production of ROS, p53 and Bax, lipid peroxidation, increased activities of SOD and CAT, and downregulates Bcl-2. By upregulating p-ERK1/2 and p-JNK, Bromuconazole disrupts the MAPK signaling pathway, impairs the cellular stress response of human trophoblast cells and endometrial cells, and damages the implantation process. Bromuconazole is applicable to research related to glioma, colon cancer, reproductive injury (implantation dysfunction), and cardiac dysfunction.
    Bromuconazole
Cat. No. Product Name / Synonyms Application Reactivity